New Investigation

Discussion in 'Cephalon' started by Walking Eagle, Feb 14, 2011 at 6:30 PM.

  1. Walking Eagle

    Walking Eagle Active Member

    Joined:
    Jul 24, 2006
    Messages:
    3,952
    Likes Received:
    11
    Cephalon once more in the limelight. When will we learn????
     

  2. Anonymous

    Anonymous Guest

    The answer my friend is blowing in the wind, the answer is blowing in the wind!

    Peter, Paul and Mary
     
  3. Anonymous

    Anonymous Guest

    Don't forget about this

    Cephalon (CEPH: Nasdaq) By Caris & Co. ($60.11, Feb. 11, 2011)

    We are downgrading our rating on Cephalon shares to Below Average from Average with a price target of $54 (6.5 times 2011 estimated earnings per share of $8.23) [down from $64].

    With another quarterly EPS beat largely driven by Provigil upside, and slow revenue growth for Nuvigil, we are increasingly concerned about EPS in 2012 and beyond as Provigil generics arrive in April 2012.

    Amid our skepticism about the late-stage pipeline, we have lowered our 2012 EPS to $4.96 from $6.01, as we no longer assume major spending declines ...
     
  4. Anonymous

    Anonymous Guest

    haha and this too because it's OVA for u people!!!

    Jefferies & Co. analyst Corey Davis cut his rating on the stock two notches, to "Underperform" from "Buy." He slashed his price target on the shares to $48 per share from $77. Davis said a generic version of Fentora should reach the market soon, and sales of the brand-name version will plunge after that happens. He added that sales of the company's sleep disorder drug Nuvigil have been disappointing, and data from Cephalon's late-stage drug candidates -- which could help bolster its revenue -- is a year away or more.

    Generic drugmaker Watson Pharmaceuticals Inc. is hoping to launch its own version of Fentora, which is used to treat extreme pain in cancer patients. Davis said Watson will probably get a favorable ruling on two of the three patents it is challenging. Once that happens, he expects the company to start selling its generic.

    "We see no reason Watson should be blocked from launching with a favorable ruling soon after Feb 15th," he wrote. Cephalon reported about $182 million in Fentora sales in 2010, and Davis expects that total to drop to around $50 million in 2012 because of generic competition.

    Cephalon's drug candidates in late-stage testing include Cinquil, a treatment for adult asthma. It is also testing its drug Nuvigil as an add-on treatment for bipolar depression and its cancer drug Treanda as a treatment for non-Hodgkin's lymphoma. Davis said Cephalon won't have data from most of its current trials for at least a year. Food and Drug Administration reviews typically last for 10 months after a company files an application for marketing approval.

    Davis also expects weaker sales of Cephalon's drug Nuvigil, saying patients are switching to Nuvigil from its older drug Provigil more slowly than he expected.
     
  5. Anonymous

    Anonymous Guest

    The issue is when will the company learn and why wasn't the latest DOJ investigation disclosed last month when Cephalon became aware of it? It is material information. What are Pappert and Baldassini thinking? The latter was brought in to make sure we acted ethically, especially since we are under a CIA (whcih we have now violated in two major ways), and the former was brought in by Frank who thought Pappert would have good political connections as a former state of PA Atty General. But what he didnt realize is that Pappert was a failure as an AG- no where near as good as Corbett and others.
    And what did these idiots due to deserve their massive bonuses? By willfully and knowingly ignore ongoing and new CIA violations?
    They should be fired and their bonuses clawed back.
     
  6. Anonymous

    Anonymous Guest

    come on!! this is bullshit. nobody in their right mind will sell off label (even by mistake). for the past 5 yrs we have been selling with our tails between our legs cautious of evrything!
    just because the republicans will not approve tax hikes does not mean the pharm companies have deep pockets for you to pick. leave us alone!
     
  7. Anonymous

    Anonymous Guest

    Where's the investigation of the fraud of the US Postal Service? This is a billion dollar taxpayer-paid scam.
     
  8. Anonymous

    Anonymous Guest

    rumors
    I love rumors
    facts can be misleading but rumors can be very revealing

    I heard they escaped
     
  9. Anonymous

    Anonymous Guest

    That is an unfair comparison of Pappert to Corbett. What is your definition of failure as an AG? If wiping your ass in a public domain (the press) with the Bill of Rights is considered in your eyes a success, then by all means Pappert is a failure.

    I personally do not like either of the two and find both contemptous individuals, but there are degrees of sleaze even with AGs. And unfortunately I think Corbett can even exceed Rendell in sleaze department now that he is in Harrisburg. And that bar is set very high!

    And bonuses are contractual. Just like us in the field they are set in stone way in advance from a budget perspective. The net effect of any pending litigation will not been seen until there is a final negative court outcome or a settlement. Then the board will ding the members of executive committee by making them fly coach and double up rooming at sales meetings.